« A disruptive technology, which can be applied in the treatment of numerous conditions »
Declaration of total number of shares and voting rights
04/02/2020
Dowload PDF File (272Ko)
THERANEXUS reports cash position as of December 31, 2019
27/01/2020
Télécharger le PDF (349Ko)
THERANEXUS announces its financial calendar for 2020
20/01/2020
Download PDF File (276Ko)
THERANEXUS announces the clinical results of its phase 1b study demonstrating the extended pharmacological profile of its drug candidate THN201 compared to donepezil
15/01/2020
Download PDF File (381 Ko)